相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment
Karthik Lingineni et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Recovery from acute kidney injury in patients with pulmonary embolism: A single-center study
Martin Murgier et al.
THROMBOSIS RESEARCH (2021)
A retrospective study of indications and consequences of monitoring direct oral anticoagulant plasma concentrations on patient care in a university hospital: The Retro-AOD study
Thibaud Cavaillez et al.
THROMBOSIS RESEARCH (2021)
Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial
An S. De Vriese et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption
Wen Kou et al.
PHARMACEUTICAL RESEARCH (2021)
Severe Inflammation, Acute Kidney Injury, and Drug-Drug Interaction: Triple Penalty for Prolonged Elimination of Apixaban in Patients With Coronavirus Disease 2019: A Grand Round
Manon Launay et al.
THERAPEUTIC DRUG MONITORING (2021)
Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries
Miklos Rohla et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2021)
Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study
Yumao Zhang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis
Toshiki Kuno et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding
Sarah Hanigan et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)
Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure
Gintautas Gumbrevicius et al.
MEDICINA-LITHUANIA (2020)
Supratheraputic rivaroxaban levels: A persistent drug-drug interaction after discontinuation of amiodarone
Kenneth Skov et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2020)
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism
Isabel Reinecke et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Liping Zhang et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism
Alexander Solms et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)
Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition
Jasleen K. Sodhi et al.
PHARMACEUTICAL RESEARCH (2020)
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Wonkyung Byon et al.
CLINICAL PHARMACOKINETICS (2019)
Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry
Martin Murgier et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2019)
Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation
Ralf E. Harskamp et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways
Andrea Huppertz et al.
BMC PHARMACOLOGY & TOXICOLOGY (2019)
Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses
Stephy George et al.
BLOOD COAGULATION & FIBRINOLYSIS (2019)
Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling
Kosuke Doki et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition
Sophie Hodin et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2018)
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection
David J. Greenblatt et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States
Konstantinos C. Siontis et al.
CIRCULATION (2018)
Pharmacokinetic variability of anticoagulants in patients with cancer associated thrombosis: Clinical consequences
Audrey Bellesoeur et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban
Ruijuan Xu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Rivaroxaban With and Without Amiodarone in Renal Impairment
Eleanor Jing Yi Cheong et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
A Rare Case of Spontaneous Cardiac Tamponade Induced by Concomitant Use of Rivaroxaban and Amiodarone
Oreoluwa Oladiran et al.
CASE REPORTS IN CARDIOLOGY (2018)
Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study
Anne Godier et al.
EUROPEAN HEART JOURNAL (2017)
Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation
Shang-Hung Chang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients
Thomas A. Mavrakanas et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial)
Jeffrey B. Washam et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism
W. Byon et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis
Xiaoli Wang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
Ming Chang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Successful hemostasis and reversal of highly elevated PT/INR after dabigatran etexilate use in a patient with acute kidney injury
Justin M. Jones et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2016)
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis
Clapton Dias et al.
AMERICAN JOURNAL OF NEPHROLOGY (2016)
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF
Kevin E. Chan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Charles E. Frost et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Fatal intracerebral bleeding under rivaroxaban
Claudia Stoellberger et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study
Siv Jonsson et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Christian T. Ruff et al.
LANCET (2015)
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2014)
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial
Benjamin A. Steinberg et al.
HEART RHYTHM (2014)
An Open-Label Study to Estimate the Effect of Steady-State Erythromycin on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban in Subjects with Renal Impairment and Normal Renal Function
Kenneth T. Moore et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Gastrointestinal bleeding under dabigatran
C. Stoellberger et al.
JOURNAL OF POSTGRADUATE MEDICINE (2014)
Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation Insights From the ARISTOTLE Trial
Greg Flaker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)
Paul A. Reilly et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Ischemic Stroke and Intestinal Bleeding Under Dabigatran in Metabolic Myopathy
Josef Finsterer et al.
CARDIOVASCULAR THERAPEUTICS (2013)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban
Donglu Zhang et al.
DRUG METABOLISM AND DISPOSITION (2013)
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice
Joseph A. Grillo et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2012)
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
Daniel E. Salazar et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
Dagmar Kubitza et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate An Open-Label, Parallel-Group, Single-Centre Study
Joachim Stangier et al.
CLINICAL PHARMACOKINETICS (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
Jeffrey I. Weitz et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
分享论文
